...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urology >Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.
【24h】

Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.

机译：经非阴囊渗透增强的睾丸激素透皮系统治疗的性腺功能减退男性的前列腺大小。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: This study examined the effects of testosterone replacement using a nonscrotal testosterone transdermal (TTD) system on prostate size and prostate-specific antigen (PSA) levels in hypogonadal men. METHODS: As part of an open-label, multicenter study, prostate volume as measured by transrectal ultrasound and PSA were assessed in 29 hypogonadal men during treatment with intramuscular testosterone enanthate (+TE), followed by 8 weeks of androgen withdrawal (-T), and then during 1 year of therapy with Androderm Testosterone Transdermal System, a nonscrotal permeation-enhanced TTD system (+TTD). RESULTS: Mean prostate volume decreased significantly from the +TE period (17 g) compared with the -T period (14 g) (P < 0.001). Prostate volume increased significantly from the -T period compared with the +TTD period (18 g) (P < 0.001). Maximum prostate size, comparable to that measured during +TE (P = 0.125), was reached by month 3 of +TTD therapy; prostate volume did not increase further during the remaining 9 months of +TTD therapy. Prostate volume correlated with age (P < 0.01) during all three periods of observation (+TE: r = 0.69; -T: r = 0.64; and +TTD: r = 0.55). No patient developed symptomatic benign prostatic hyperplasia during the treatment period. PSA levels decreased during androgen withdrawal compared with levels measured during +TE treatment (P < 0.001) and rose with resumption of androgen therapy with TTD (P < 0.006). However, PSA levels during +TTD replacement remained significantly lower (P < 0.001) than during +TE replacement. CONCLUSIONS: Physiologic testosterone replacement in hypogonadal men was achieved using the TTD system. Prostate size during therapy with TTD was comparable to that reported for normal men. In these men treated with TTD, PSA levels were also within the normal range.
机译：目的：本研究研究了使用非阴囊睾丸激素透皮（TTD）系统替代睾丸激素对性腺功能减退男性前列腺大小和前列腺特异性抗原（PSA）的影响。方法：作为一项开放性，多中心研究的一部分，在29名性腺功能减退男性中，经肌肉内睾丸酮庚酸酯（+ TE）进行治疗，随后进行了8周的雄性激素戒断（-T），评估了经直肠超声和PSA测量的前列腺体积。 ，然后在使用Androderm睾丸激素透皮系统（一种非阴囊渗透增强的TTD系统（+ TTD））治疗的1年期间。结果：与-T期（14 g）相比，+ TE期（17 g）的平均前列腺体积显着下降（P <0.001）。与+ TTD期间（18 g）相比，-T期间前列腺体积显着增加（P <0.001）。在+ TTD治疗的第3个月达到了与+ TE期间测得的最大前列腺大小（P = 0.125）相当;在+ TTD治疗的剩余9个月中，前列腺体积并未进一步增加。在所有三个观察期中，前列腺体积与年龄相关（P <0.01）（+ TE：r = 0.69; -T：r = 0.64; + TTD：r = 0.55）。在治疗期间，没有患者出现症状性良性前列腺增生。与+ TE治疗期间测得的水平相比，雄激素戒断期间的PSA水平降低（P <0.001），TTD恢复雄激素治疗后PSA水平升高（P <0.006）。然而，+ TTD置换期间的PSA水平仍显着低于+ TE置换期间的PSA水平（P <0.001）。结论：使用TTD系统可实现性腺功能减退男性的生理性睾丸激素替代。 TTD治疗期间的前列腺大小可与正常男性报告的相当。在接受TTD治疗的这些男性中，PSA水平也在正常范围内。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号